CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for bluebird bio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

bluebird bio Inc
455 Grand Union Boulevard
Phone: (339) 499-9300p:339 499-9300 SOMERVILLE, MA  02145  United States Ticker: BLUEBLUE
On March 24, 2024, the Audit Committee of the Board of Directors of bluebird bio Inc, based on the recommendation of management and after consultation with Ernst & Young LLP, concluded that the company’s previously-issued audited consolidated financial statements for each fiscal year beginning January 1, 2019 and its previously-issued unaudited interim condensed consolidated financial statements for each of the first three quarters in such years, as well as the associated earnings releases and investor presentations or other communications describing such financial statements, were materially misstated and, accordingly, should no longer be relied upon. Specifically, the identified errors resulted from the company’s identification of embedded leases and the application of its accounting policy for the treatment of non-lease components contained in lease agreements.
Business Summary
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). It is focused on pursuing curative gene therapies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board MarkVachon 65 1/1/2022 7/16/2014
President, Chief Executive Officer, Director AndrewObenshain 50 11/4/2021 11/4/2021
Chief Financial Officer O. JamesSterling 54 6/10/2024 6/10/2024
7 additional Officers and Directors records available in full report.

Business Names
Business Name
BLUE
bluebird bio (Bermuda) Ltd.
bluebird bio (FR) SAS
11 additional Business Names available in full report.

General Information
Number of Employees: 375 (As of 12/31/2023)
Outstanding Shares: 194,444,345 (As of 11/12/2024)
Shareholders: 8
Stock Exchange: NASD
Federal Tax Id: 133680878
Fax Number: (302) 636-5454
Email Address: info@bluebirdbio.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024